The AACR Grants Program invests in promising cancer scientists at all career levels to sustain the pipeline of progress. Since 1993, the AACR has distributed more than $547 million in grants to foster innovation in basic, translational, and clinical research.
The AACR’s network of funding partners expanded significantly in 2022 with the establishment of four new funder relationships:
As part of its core values of diversity, equity, and inclusion, the AACR is committed to the goal of ensuring that the cancer workforce is as diverse as the patients that it serves. The AACR Grants Program made significant strides toward reaching that goal in 2022 by aggressively funding meritorious investigators from diverse backgrounds that are underrepresented in the cancer research community— including women, individuals working in low- and middle-income countries, and members of racial or ethnic minorities. Eighteen grants supporting diversity, equity, and inclusion totaling more than $4.75 million were awarded in 2022, launching promising careers that will help prevent and cure all cancers and serve all communities.
Grants were awarded in 2022 to meritorious scientists from nearly 50 institutions to support innovative cancer science.
Amount of research grant funding awarded to 24 postdoctoral and clinical fellows to advance their career development in 2022.
Expert scientists served on 24 scientific review committees to select the 2022 grant recipients. The AACR is a trusted administrator of research grants, providing fair, rigorous, and transparent peer review.
Applications for AACR grants from the United States and 31 other countries were evaluated in 2022.
Amount awarded to 56 independent investigators at all career levels—including young investigators, mid-career researchers, and established scientists—to support meritorious cancer research.
A division of the Entertainment Industry Foundation, Stand Up To Cancer (SU2C) supports collaboration and innovation in translational cancer science to accelerate the development of new cancer treatments. As the Scientific Partner of SU2C, the AACR provides expert peer review and grants administration, ensuring that SU2C’s groundbreaking funding models deliver outstanding results.
The Pancreatic Cancer Collective (PCC) is a strategic partnership between SU2C and the Lustgarten Foundation that was founded in 2009 to improve outcomes for a disease with a current five-year survival rate of 11 percent. In September, the AACR provided a productive venue for the PCC’s Annual Symposium, allowing the symposium to be held just before the start of the eighth AACR Special Conference on Pancreatic Cancer in Boston. Symposium participants were also able to attend the AACR conference, forming connections and collaborations with leaders in this vital field.
During its 115th anniversary event, the AACR acknowledged the vital role of philanthropic organizations—including SU2C—in funding critical advances in cancer research. In recognition of their long-standing partnership to improve the lives of patients with cancer, the AACR presented SU2C President and CEO Russell Chew and the SU2C Founders, Advisors, and Scientific Advisory Committee with the AACR Outstanding Achievement Award for Service to Cancer Science and Medicine.